Stockreport

Regeneron Presents Positive Data at ASH for REGN1979 CD20xCD3 Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Regeneron Pharmaceuticals, Inc.  (REGN) 
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
PDF TARRYTOWN, N.Y., Dec. 1, 2018 /PRNewswire/ -- 100% overall and 80% complete response rate in 10 patients with relapsed or refractory follicular lymphoma treated with 5 m [Read more]